What is Promacta, and how does it work?
Promacta, also known as eltrombopag, is an oral medication used to treat low platelet counts in patients with certain medical conditions [1]. It is a thrombopoietin receptor agonist, which means it stimulates the production of platelets in the bone marrow [2]. This medication is often prescribed for patients with chronic immune thrombocytopenia (ITP), essential thrombocythemia (ET), and aplastic anemia.
How does Promacta compare with other treatments for low platelet counts?
Promacta has been shown to be effective in increasing platelet counts in patients with low platelet counts due to ITP, ET, and aplastic anemia. It works by stimulating the production of platelets in the bone marrow, which helps to increase platelet counts and reduce the risk of bleeding complications [3]. In comparison, other treatments for low platelet counts, such as corticosteroids and immunoglobulin therapy, may have different mechanisms of action and varying degrees of efficacy.
When is Promacta prescribed, and who is eligible for treatment?
Promacta is typically prescribed for patients with a history of low platelet counts (thrombocytopenia) due to ITP, ET, or aplastic anemia. Patients who are eligible for treatment with Promacta are usually those who have not responded to other treatments or have severe bleeding complications [4]. It is essential for patients to discuss their eligibility for Promacta with their healthcare provider, as it may not be suitable for everyone.
What side effects can Promacta cause, and how can they be managed?
Common side effects of Promacta include nausea, vomiting, diarrhea, and fatigue [5]. More severe side effects can occur, such as liver damage, an increase in liver enzymes, or changes in liver function tests. To manage side effects, patients should discuss their treatment plan with their healthcare provider and follow their recommendations for monitoring and managing side effects.
Is Promacta available in generic form or as a biosimilar?
Promacta is a proprietary medication marketed by Novartis, and it does not have a generic or biosimilar version available in the market yet [6]. Patients who are prescribed Promacta should be aware that the cost of the medication may be high, and they may need to discuss their options with their healthcare provider or insurance company for coverage.
Sources:
[1] Novartis. (n.d.). Promacta (eltrombopag) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050782s017lbl.pdf
[2] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Platelets and bleeding. Retrieved from https://www.niddk.nih.gov/health-information/thrombocytopenia/platelets-and-bleeding
[3] ClinicalTrials.gov. (n.d.). Promacta (eltrombopag) for treating patients with low platelet counts due to ITP, ET, or aplastic anemia. Retrieved from https://clinicaltrials.gov/ct2/show/NCT01016135
[4] Mayo Clinic. (n.d.). Low platelet count (thrombocytopenia). Retrieved from https://www.mayoclinic.org/symptoms/low-platelet-count/basics/definition/sym-20051048
[5] MedlinePlus. (n.d.). Eltrombopag. Retrieved from https://medlineplus.gov/druginfo/meds/a607030.html
[6] IQVIA Institute. (2022). Promacta (eltrombopag). Retrieved from https://www.iqvia.com/institute/daily-dose/promacta-eltrombopag